Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease

Growth Horm IGF Res. 2023 Aug;71:101548. doi: 10.1016/j.ghir.2023.101548. Epub 2023 Jul 22.ABSTRACTInsulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.PMID:37598644 | DOI:10.1016/j.ghir.2023.101548
Source: Growth Hormone and IGF Research - Category: Endocrinology Authors: Source Type: research